The Roth Capital Reaffirmed Buy Rating for Stemline Therapeutics Inc. (STML)

The Roth Capital Reaffirmed Buy Rating for Stemline Therapeutics Inc. (STML)

Roth Capital reaffirmed their buy rating on shares of Stemline Therapeutics Inc. (NASDAQ:STML) in a research note issued to investors on Wednesday. They currently have a $32.00 price objective on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the company. HC Wainwright restated a buy rating on shares of Stemline Therapeutics in a report on Monday, November 21st. Zacks Investment Research cut Stemline Therapeutics from a hold rating to a sell rating in a report on Friday, November 11th. Wedbush restated an outperform rating and set a $15.00 price target on shares of Stemline Therapeutics in a report on Tuesday, November 8th. Finally, Jefferies Group restated a buy rating on shares of Stemline Therapeutics in a report on Friday, August 5th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $20.50.

Stemline Therapeutics (NASDAQ:STML) opened at 13.50 on Wednesday. Stemline Therapeutics has a one year low of $3.88 and a one year high of $14.20. The firm’s market capitalization is $240.92 million. The company’s 50-day moving average is $12.22 and its 200-day moving average is $8.93.

Several institutional investors have recently modified their holdings of the company. California State Teachers Retirement System boosted its position in shares of Stemline Therapeutics by 0.8% in the third quarter. California State Teachers Retirement System now owns 35,649 shares of the biopharmaceutical company’s stock worth $386,000 after buying an additional 300 shares in the last quarter. Oak Ridge Investments LLC boosted its position in shares of Stemline Therapeutics by 26.3% in the third quarter. Oak Ridge Investments LLC now owns 12,796 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 2,663 shares in the last quarter. Carl Domino Inc boosted its position in shares of Stemline Therapeutics by 12.9% in the second quarter. Carl Domino Inc now owns 26,305 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 3,000 shares in the last quarter. Teachers Advisors LLC boosted its position in shares of Stemline Therapeutics by 17.8% in the third quarter. Teachers Advisors LLC now owns 26,913 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 4,060 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Stemline Therapeutics by 1.9% in the second quarter. State Street Corp now owns 220,768 shares of the biopharmaceutical company’s stock worth $1,493,000 after buying an additional 4,197 shares in the last quarter. Institutional investors own 46.73% of the company’s stock.

Stemline Therapeutics Company Profile

Related posts

Leave a Comment